Zachary Boyd

7.0k total citations · 2 hit papers
27 papers, 3.7k citations indexed

About

Zachary Boyd is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Zachary Boyd has authored 27 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in Zachary Boyd's work include Cancer Immunotherapy and Biomarkers (16 papers), Bladder and Urothelial Cancer Treatments (9 papers) and Ferroptosis and cancer prognosis (6 papers). Zachary Boyd is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), Bladder and Urothelial Cancer Treatments (9 papers) and Ferroptosis and cancer prognosis (6 papers). Zachary Boyd collaborates with scholars based in United States, United Kingdom and France. Zachary Boyd's co-authors include Priti S. Hegde, Gregg Fine, Yohann Loriot, Daniel P. Petrylak, Joaquim Bellmunt, Thomas Powles, Nicholas J. Vogelzang, Howard A. Burris, Xiaodong Shen and Cristina Cruz and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Immunity.

In The Last Decade

Zachary Boyd

26 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

2014 1.9k citations Thomas Powles, Joseph P. Eder et al. Nature profile →
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

2020 274 citations Bruno Sangro, Ignacio Melero et al. Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zachary Boyd United States	14	2.3k	1.2k	1.1k	731	705	27	3.7k
Ryusei Matsuyama Japan	37	1.8k 0.8×	592 0.5×	1.1k 1.0×	869 1.2×	814 1.2×	168	3.8k
Karim A. Benhadji United States	32	2.1k 0.9×	669 0.6×	1.8k 1.7×	540 0.7×	573 0.8×	117	3.8k
Baocai Xing China	30	1.7k 0.7×	1.2k 1.0×	1.7k 1.6×	825 1.1×	480 0.7×	124	3.9k
Alexandre Calon Spain	15	2.7k 1.1×	1.0k 0.8×	1.6k 1.5×	981 1.3×	254 0.4×	23	4.0k
Sean P. Pitroda United States	33	1.8k 0.8×	933 0.8×	1.1k 1.1×	677 0.9×	342 0.5×	94	3.4k
Yoshinori Ino Japan	34	1.3k 0.6×	660 0.6×	1.7k 1.6×	517 0.7×	366 0.5×	63	3.5k
Akihito Kawazoe Japan	27	3.1k 1.3×	1.1k 0.9×	647 0.6×	503 0.7×	913 1.3×	101	4.4k
Daniele V. F. Tauriello Netherlands	19	3.0k 1.3×	1.2k 1.0×	2.3k 2.1×	1.1k 1.4×	270 0.4×	34	4.9k
Shijun Kang China	12	2.0k 0.9×	1.2k 1.0×	881 0.8×	552 0.8×	258 0.4×	22	3.0k
Tessa Fredriksen France	7	2.6k 1.1×	2.0k 1.7×	1.6k 1.5×	1.1k 1.5×	331 0.5×	8	4.7k

Countries citing papers authored by Zachary Boyd

Since Specialization

Citations

This map shows the geographic impact of Zachary Boyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zachary Boyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zachary Boyd more than expected).

Fields of papers citing papers by Zachary Boyd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zachary Boyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zachary Boyd. The network helps show where Zachary Boyd may publish in the future.

Co-authorship network of co-authors of Zachary Boyd

This figure shows the co-authorship network connecting the top 25 collaborators of Zachary Boyd. A scholar is included among the top collaborators of Zachary Boyd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zachary Boyd. Zachary Boyd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lei, Ming, Nathan O. Siemers, Dimple Pandya, et al.. (2021). Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. Clinical Cancer Research. 27(14). 3926–3935. 57 indexed citations

Sangro, Bruno, Ignacio Melero, Samir Wadhawan, et al.. (2020). Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. Journal of Hepatology. 73(6). 1460–1469. 274 indexed citations breakdown →

Lei, Ming, Nathan O. Siemers, Dimple Pandya, et al.. (2019). Abstract 2673: Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC). Cancer Research. 79(13_Supplement). 2673–2673. 12 indexed citations

Lenz, Heinz‐Josef, Eric Van Cutsem, María Luisa Limón, et al.. (2018). Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Annals of Oncology. 29. viii714–viii714. 68 indexed citations

Scheerens, Heleen, Zachary Boyd, Vivek P. Gupta, et al.. (2017). Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch. Clinical and Translational Science. 10(2). 84–92. 81 indexed citations

Williams, Jacqueline P., Marcin Kowanetz, Hartmut Koeppen, et al.. (2016). The SP142 PD-L1 IHC assay for atezolizumab (atezo) reflects pre-existing immune status in NSCLC and correlates with PD-L1 mRNA. Annals of Oncology. 27. vi405–vi405. 1 indexed citations

Boyd, Zachary, Dustin Smith, Brian M. Baker, et al.. (2016). Abstract B001: Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab. Cancer Immunology Research. 4(1_Supplement). B001–B001. 9 indexed citations

Rosenberg, Jonathan E., Daniel P. Petrylak, Michiel Simon Van Der Heijden, et al.. (2016). PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).. Journal of Clinical Oncology. 34(15_suppl). 104–104. 36 indexed citations

Powles, Thomas, Dorothee Nickles, Eliezer M. Van Allen, et al.. (2015). Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC). Journal for ImmunoTherapy of Cancer. 3(S2). 11 indexed citations

10.

Kim, Joseph W., Joaquim Bellmunt, Thomas Powles, et al.. (2015). Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study.. Journal of Clinical Oncology. 33(7_suppl). 297–297. 10 indexed citations

11.

Gettinger, Scott, Marcin Kowanetz, Hartmut Koeppen, et al.. (2015). Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A.. Journal of Clinical Oncology. 33(15_suppl). 3015–3015. 10 indexed citations

12.

Powles, Thomas, Joseph P. Eder, Gregg Fine, et al.. (2014). MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 515(7528). 558–562. 1850 indexed citations breakdown →

13.

Xiao, Yuanyuan, Christina Rabe, Marcin Kowanetz, et al.. (2014). Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer (UBC). 5. 1 indexed citations

14.

Bellmunt, Joaquim, Daniel P. Petrylak, Thomas Powles, et al.. (2014). Inhibition of Pd-L1 By Mpdl3280A Leads to Clinical Activity in Pts with Metastatic Urothelial Bladder Cancer (Ubc). Annals of Oncology. 25. iv280–iv280. 12 indexed citations

15.

Lackner, Mark R., Alex Adai, Nancy Yu, et al.. (2011). miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast CancerA presentation from the Keystone Symposium on Epithelial Plasticity and Epithelial to Mesenchymal Transition, Vancouver, Canada, 21 to 26 January 2011. This Presentation also complements the Science Signaling Research Article by Stinson et al. published 14 June 2011.. Science Signaling. 4(186). pt5–pt5. 118 indexed citations

16.

Hoeflich, Klaus P., Carol O’Brien, Zachary Boyd, et al.. (2009). In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models. Clinical Cancer Research. 15(14). 4649–4664. 385 indexed citations

17.

Boyd, Zachary, Qun Wu, Carol O’Brien, et al.. (2008). Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Molecular Cancer Therapeutics. 7(12). 3695–3706. 51 indexed citations

18.

Yu, Jianhua, Wei Min, Zachary Boyd, et al.. (2007). Transcriptional control of human T‐BET expression: The role of Sp1. European Journal of Immunology. 37(9). 2549–2561. 29 indexed citations

19.

Yu, Jianhua, Wei Min, Brian Becknell, et al.. (2006). Pro- and Antiinflammatory Cytokine Signaling: Reciprocal Antagonism Regulates Interferon-gamma Production by Human Natural Killer Cells. Immunity. 24(5). 575–590. 223 indexed citations

20.

Boyd, Zachary, et al.. (2003). IL-10 Promotes Survival of Retinal Ganglion Cells without Activating Akt and STAT Signaling Pathways. 44(13). 125–125. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact